Screening for inherited thrombophilia in asymptomatic individuals
- Kenneth A Bauer, MD
Kenneth A Bauer, MD
- Professor of Medicine
- Harvard Medical School
Inherited thrombophilia denotes several genetic risk factors that predispose individuals to developing venous thromboembolism. Factor V Leiden is the most common. The prothrombin gene mutation, deficiencies in protein S, protein C, and antithrombin account for most of the remaining cases, while rare causes include certain dysfibrinogenemias. The total prevalence of an inherited thrombophilia in patients with a deep vein thrombosis varies based upon patient selection and ethnicity; in Caucasian populations, it can be as high as 40 percent overall compared with about 10 percent in controls. (See "Overview of the causes of venous thrombosis", section on 'Inherited thrombophilia'.)
This review will discuss the usefulness of screening for these conditions in various asymptomatic populations [1,2]. The diagnostic approach to the patient presenting with thrombosis and management of inherited thrombophilias are discussed separately. (See "Evaluating patients with established venous thromboembolism for acquired and inherited risk factors" and "Factor V Leiden and activated protein C resistance" and "Prothrombin G20210A mutation" and "Antithrombin deficiency" and "Protein C deficiency" and "Protein S deficiency".)
GENERAL SCREENING ISSUES
Screening techniques are used clinically to identify individuals at risk for a preventable disease or complication. Reliable assays are now available to test for the presence of the various causes of inherited thrombophilia (table 1).
However, unselected population-based screening for inherited thrombophilia is not recommended because of three salient factors:
●The low frequency of the symptomatic condition in the general population (table 2)To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:
- Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114:512.
- Baglin T, Gray E, Greaves M, et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010; 149:209.
- Schambeck CM, Schwender S, Haubitz I, et al. Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives? Thromb Haemost 1997; 78:1480.
- Di Minno MN, Ambrosino P, Ageno W, et al. Natural anticoagulants deficiency and the risk of venous thromboembolism: a meta-analysis of observational studies. Thromb Res 2015; 135:923.
- Martinelli I, Mannucci PM, De Stefano V, et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: a study of 150 families. Blood 1998; 92:2353.
- Lijfering WM, Brouwer JL, Veeger NJ, et al. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood 2009; 113:5314.
- Holzhauer S, Goldenberg NA, Junker R, et al. Inherited thrombophilia in children with venous thromboembolism and the familial risk of thromboembolism: an observational study. Blood 2012; 120:1510.
- Middeldorp S, Henkens CM, Koopman MM, et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998; 128:15.
- Middeldorp S, Meinardi JR, Koopman MM, et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med 2001; 135:322.
- Coppens M, van de Poel MH, Bank I, et al. A prospective cohort study on the absolute incidence of venous thromboembolism and arterial cardiovascular disease in asymptomatic carriers of the prothrombin 20210A mutation. Blood 2006; 108:2604.
- Mannucci PM. Genetic hypercoagulability: prevention suggests testing family members. Blood 2001; 98:21.
- Mahmoodi BK, Brouwer JL, Ten Kate MK, et al. A prospective cohort study on the absolute risks of venous thromboembolism and predictive value of screening asymptomatic relatives of patients with hereditary deficiencies of protein S, protein C or antithrombin. J Thromb Haemost 2010; 8:1193.
- Connors JM. Thrombophilia Testing and Venous Thrombosis. N Engl J Med 2017; 377:1177.
- Green D. Genetic hypercoagulability: screening should be an informed choice. Blood 2001; 98:20.
- Koeleman BP, Reitsma PH, Bertina RM. Familial thrombophilia: a complex genetic disorder. Semin Hematol 1997; 34:256.
- Bucciarelli P, De Stefano V, Passamonti SM, et al. Influence of proband's characteristics on the risk for venous thromboembolism in relatives with factor V Leiden or prothrombin G20210A polymorphisms. Blood 2013; 122:2555.
- Conard J, Horellou MH, Van Dreden P, et al. Thrombosis and pregnancy in congenital deficiencies in AT III, protein C or protein S: study of 78 women. Thromb Haemost 1990; 63:319.
- Creinin MD, Lisman R, Strickler RC. Screening for factor V Leiden mutation before prescribing combination oral contraceptives. Fertil Steril 1999; 72:646.
- Wu O, Robertson L, Langhorne P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thromb Haemost 2005; 94:17.
- Wu O, Robertson L, Twaddle S, et al. Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol 2005; 131:80.
- Wu O, Greer IA. Is screening for thrombophilia cost-effective? Curr Opin Hematol 2007; 14:500.
- Middeldorp S. Thrombosis in women: what are the knowledge gaps in 2013? J Thromb Haemost 2013; 11 Suppl 1:180.
- van Vlijmen EF, Brouwer JL, Veeger NJ, et al. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study. Arch Intern Med 2007; 167:282.
- Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ 1996; 313:1127.
- Dalen JE. Should patients with venous thromboembolism be screened for thrombophilia? Am J Med 2008; 121:458.
- Sachs BP, Brown DA, Driscoll SG, et al. Maternal mortality in Massachusetts. Trends and prevention. N Engl J Med 1987; 316:667.
- McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78:1183.
- van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briët E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 1993; 153:1557.
- Rouse DJ, Goldenberg RL, Wenstrom KD. Antenatal screening for factor V Leiden mutation: a critical appraisal. Obstet Gynecol 1997; 90:848.
- GENERAL SCREENING ISSUES
- Arguments against screening
- Arguments in favor of screening
- SCREENING FOR SPECIFIC INHERITED THROMBOPHILIAS
- Factor V Leiden
- Homozygosity and multiple defects
- Protein C deficiency
- Antithrombin deficiency
- SCREENING IN HIGH RISK SITUATIONS
- Oral contraceptives
- Obstetric complications
- DEFECTS FOR WHICH SCREENING IS NOT HELPFUL
- Homocysteine, MTHFR variants, and PAI-1 4G/5G promoter variants
- Elevated coagulation factor levels
- INFORMATION FOR PATIENTS